IFP Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

IFP Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32	Hold	30	–	–	﹤0.01%	5101
2026 Q2	$100	Hold	30	–	–	﹤0.01%	4957
2026 Q1	$154	Hold	30	–	–	﹤0.01%	4663
2025 Q4	$203	Hold	30	–	–	﹤0.01%	4477
2025 Q3	$415	Hold	30	–	–	﹤0.01%	4235
2025 Q2	$362	Hold	30	–	–	﹤0.01%	4512
2025 Q1	$529	Buy	+30	New	+$552	﹤0.01%	3453

Other funds holding CVKD

Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors's CVKD Position: Q3 2026 in Review

IFP Advisors held its Cadrenal Therapeutics (CVKD) position steady in Q3 2026 at 30 shares worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #5101.

IFP Advisors first reported a position in CVKD in Q1 2025 and has held it in 7 quarters since. The position peaked at $529 in Q1 2025. 5 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

IFP Advisors held 30 shares of Cadrenal Therapeutics worth $32 as of Q3 2026.
IFP Advisors left its Cadrenal Therapeutics share count unchanged in Q3 2026.
Cadrenal Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5101 holding.
IFP Advisors first reported a position in Cadrenal Therapeutics in Q1 2025 and has held it in 7 quarters since.
IFP Advisors's Cadrenal Therapeutics position peaked at $529 in Q1 2025.
5 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.